Bone Biologics Corp (BBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bone Biologics Corp (BBLG) has a cash flow conversion efficiency ratio of -0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-714.76K) by net assets ($5.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bone Biologics Corp balance sheet quality to measure how much of total assets are equity-financed.
Bone Biologics Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Bone Biologics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Bone Biologics Corp (BBLG) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Bone Biologics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Biologics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
0.074x |
|
Central China Real Estate Limited
F:AJ5
|
-0.088x |
|
ExpreS2ion Biotech Holding AB
ST:EXPRS2
|
-0.965x |
|
CBEYOND
F:C5B
|
0.724x |
|
Labrador Technologies Inc
V:LTX
|
0.099x |
|
Biosergen AS
ST:BIOSGN
|
-0.954x |
|
Avinger Inc
NASDAQ:AVGR
|
-0.738x |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
0.350x |
Annual Cash Flow Conversion Efficiency for Bone Biologics Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Bone Biologics Corp from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see BBLG market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.38 Million | $-2.69 Million | -0.500x | +57.74% |
| 2024-12-31 | $3.48 Million | $-4.12 Million | -1.184x | +63.99% |
| 2023-12-31 | $2.91 Million | $-9.56 Million | -3.288x | -448.21% |
| 2022-12-31 | $5.95 Million | $-3.57 Million | -0.600x | -220.99% |
| 2021-12-31 | $6.58 Million | $-1.23 Million | -0.187x | -699.23% |
| 2020-12-31 | $-13.69 Million | $-426.93K | 0.031x | -88.62% |
| 2019-12-31 | $-11.87 Million | $-3.25 Million | 0.274x | -42.62% |
| 2018-12-31 | $-8.60 Million | $-4.10 Million | 0.477x | +20.37% |
| 2017-12-31 | $-8.40 Million | $-3.33 Million | 0.397x | -53.27% |
| 2016-12-31 | $-8.63 Million | $-7.33 Million | 0.849x | +35.98% |
| 2015-12-31 | $-5.68 Million | $-3.55 Million | 0.624x | -16.23% |
| 2014-12-31 | $-3.70 Million | $-2.76 Million | 0.745x | +68218.73% |
| 2013-12-31 | $-5.61 Million | $-6.12K | 0.001x | -98.86% |
| 2012-12-31 | $-4.68K | $-447.00 | 0.096x | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more